The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib

Abstract

In recently published articles, the superior outcome of infant patients with high-grade gliomas (HGGs) when compared with older children was demonstrated. Receptor tyrosine kinase (RTK) gene fusions highlight the distinct biology of infant HGGs and could provide the rationale for utilization of targeted therapy. Here, we describe a case of ETV6-NTRK3-positive infant HGG successfully treated with the TRK/ROS1/ALK inhibitor entrectinib. To date, reports of fusion-targeting therapy in these patients remain sparse.